Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2021 09:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Receives $20 Million From Ocumension Therapeutics

Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone paymentsOcumension makes a $10 million equity investment in...
April 09, 2021 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021

ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
March 18, 2021 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference

ATLANTA, March 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
March 17, 2021 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland

ATLANTA, March 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
March 11, 2021 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

ATLANTA, March 11, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
March 02, 2021 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
February 24, 2021 16:05 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Reports Fourth Quarter and 2020 Results

Fourth Quarter Highlights: Consolidated Net Revenue of $13.8 Million Up 10% vs. Third Quarter of 2020 Consolidated Net Revenue Down 20% vs. Fourth Quarter of 2019 Due to COVID-19...
February 18, 2021 08:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications

ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
February 17, 2021 08:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update

ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
February 15, 2021 08:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference

ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right